IC
PRAX icon

Ikarian Capital’s Praxis Precision Medicines PRAX Stock Holding History

Ikarian Capital’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,225
Closed -$17.5M – 167
2024
Q2 		$17.5M Buy
+4,225
New +$200K 3.04% 9

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Ikarian Capital's PRAX Position: Q1 2026 in Review

Ikarian Capital reduced its Praxis Precision Medicines (PRAX) stake by 17% in Q1 2026, selling an estimated $4.64M and leaving 71,581 shares worth $23.1M. The position accounts for 1.87% of the portfolio, ranked #13.

Ikarian Capital first reported a position in PRAX in Q4 2020 and has held it in 10 quarters since. The position peaked at $25.5M in Q4 2025. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • Ikarian Capital held 71,581 shares of Praxis Precision Medicines worth $23.1M as of Q1 2026.
  • Ikarian Capital sold 15,000 Praxis Precision Medicines shares in Q1 2026, an estimated $4.64M.
  • Praxis Precision Medicines made up 1.87% of Ikarian Capital's portfolio in Q1 2026, its #13 holding.
  • Ikarian Capital first reported a position in Praxis Precision Medicines in Q4 2020 and has held it in 10 quarters since.
  • Ikarian Capital's Praxis Precision Medicines position peaked at $25.5M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.